Malignant transformation of infantile hemangioma to angiosarcoma: Response to chemotherapy with bevacizumab

Authors

  • Michael R. Jeng MD,

    Corresponding author
    1. Division of Pediatric Hematology/Oncology/Stem Cell Transplantation/Cancer Biology, Stanford University School of Medicine, Palo Alto, California
    • Correspondence to: Michael R. Jeng, Department of Pediatrics, Hematology/Oncology/Stem Cell Transplantation, Stanford University School of Medicine, 1000 Welch Road, Suite 300, Palo Alto, CA 94304.

      E-mail: mjeng@stanford.edu

    Search for more papers by this author
  • Beng Fuh MD,

    1. Division of Pediatric Hematology/Oncology, East Carolina University Brody School of Medicine, Greenville, North Carolina
    Search for more papers by this author
  • Julie Blatt MD,

    1. Division of Pediatric Hematology/Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
    Search for more papers by this author
  • Anita Gupta MD,

    1. Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio
    Search for more papers by this author
  • Arnold C. Merrow MD,

    1. Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio
    Search for more papers by this author
  • Adrienne Hammill MD, PhD,

    1. Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio
    Search for more papers by this author
  • Denise Adams MD

    1. Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio
    Search for more papers by this author

  • Conflict of interest: Nothing to report.

Abstract

We describe a child initially diagnosed with multi-focal infantile hemangioma (cutaneous, hepatic, pulmonary), a benign vascular lesion, which underwent malignant transformation to angiosarcoma. The use of anti-angiogenic agents, such as bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, has been reported in adults with angiosarcoma. Treatment with chemotherapy (gemcitabine and docetaxel) and bevacizumab resulted in disease response with progression free survival of 12 months. This report describes the response to chemotherapy and bevacizumab in a child with angiosarcoma and highlights the potential for malignant transformation of benign vascular lesions and the need for careful monitoring. Pediatr Blood Cancer 2014;61:2115–2117. © 2014 Wiley Periodicals, Inc.

Ancillary